NYSE listed, Lausanne-based ADC Therapeutics (ADCT), a commercial-stage biotech focused on its next-generation, targeted antibody drug conjugates (ADCs), has priced an underwritten offering of 12 million of its common shares…
NYSE listed, Lausanne-based ADC Therapeutics (ADCT), a commercial-stage biotech focused on its next-generation, targeted antibody drug conjugates (ADCs), has priced an underwritten offering of 12 million of its common shares…
…
Rankings & Reports
M&A
Equity
Healthcare Investing Review
Healthcare Real Assets Report
Resources & Events
Resource Hub
Sector Events
Private Capital Conference
Real Assets Conference